Regimens are being provided to individual states free of charge, pending EUA.
The Omicron variant of the COVID-19 virus burned itself out almost as quickly as it created record surges in infections, but patients affected by any lingering cases may soon have a welcome solution.
The federal government announced last week that it was purchasing 600,000 treatment courses of a new monoclonal antibody treatment shown to be effective against the new variant. The antibody regimen, known as bebtelovimab, is manufactured by Eli Lilly and Company, and if it receives emergency use authorization (EUA) by the U.S. Food and Drug Administration (FDA), the U.S. Department of Health and Human Services (HHS) will make the treatment available to states free of charge.
“Under President Biden’s leadership, we are prepared for the challenges we face with COVID-19 and are laser-focused on saving lives,” HHS Secretary Xavier Becerra said in a statement. “We have more COVID-19 treatments than ever before, we are providing a billion free at-home tests, and we have enough vaccines to get everyone vaccinated and boosted. If authorized by FDA, this purchase will add an additional 600,000 courses of treatment to our nation’s ‘medicine cabinet’ that could help prevent severe outcomes for Americans who do get sick with COVID-19. Our top priority is preventing people from getting sick in the first place, which is why it is critical that Americans continue to get vaccinated and get their booster shot as soon as they’re eligible.”
HHS indicated in its announcement that it expects to receive approximately 300,000 treatment courses of the monoclonal antibody by the end of February, and approximately 300,000 more treatment courses in March.
HHS added that early data suggests that the new treatment not only is effective against the Omicron strain, but also the BA.2 Omicron subvariant, which carries the potential for creating a national surge of its own.
“We want to make sure if an American gets sick with COVID-19, they can get a treatment that works,” Becerra said.
Since the start of 2022, HHS has reportedly already provided more than 2.5 million COVID-19 treatments and therapies to states for Americans who get sick with COVID-19 to use, including antiviral pills, monoclonal antibodies, and pre-exposure prophylaxis therapies for people with compromised immune systems. The new contract also includes a future option for 500,000 more doses, and was awarded as a result of collaboration between the HHS Office of the Assistant Secretary for Preparedness and Response (ASPR) and the U.S. Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense.
The COVID-19 virus and its variants have reportedly sickened more than 418 million people and killed more than 5.8 million worldwide, including nearly 80 million illnesses and nearly 950,000 deaths in the U.S. alone.
EDITOR’S NOTE: ICD10monitor Publisher and Talk Ten Tuesdays program host Chuck Buck recently asked longtime national ICD10monitor correspondent Mark Spivey to produce a feature article on
The PHE has ended and the three-day SNF rule has returned. Following up on my previous article posted in April regarding the return of the
Please log in to your account to comment on this article.
Dr. Ronald Hirsch provides tried-and-true strategies and insight into outpatient in hospital bed stays including determining the applicable definition, who uses it, and when and how to bill for this circumstance, solidified with concrete case examples and expert insight.
Practical solutions for CDM departments to protect your hospital’s revenue.
This webcast teaches hospitals how to comply with CMS price transparency rules and compare their rates with peer hospitals. It covers creating a compliant machine-readable file, comparing negotiated rates, and improving pricing decisions.
The No Surprises Act (NSA) presents a challenge for hospitals and providers who must provide Good Faith Estimates (GFEs) for all schedulable services for self-pay and uninsured patients. Compliance is necessary, but few hospitals have been able to fully comply with the requirements despite being a year into the NSA. This webcast provides an overview of the NSA/GFE policy, its impact, and a step-by-step process to adhere to the requirements and avoid non-compliance penalties.
This expert-guided webcast will showcase tips for providers to ensure appropriate capture of the work performed for a visit. Comprehensive examples will be given that demonstrate documentation gaps and how to educate providers on the documentation necessary to appropriately assign a level of service. You will gain clarification on answers regarding emergency department and urgent care coding circumstances as well as a review of how/when it is appropriate to code for E&M in radiology and more.
Set yourself up for financial and compliance success with expert guidance that breaks down the impactful changes including MS-DRG methodology, surgical hierarchy updates, and many new technology add-on payments (NTAPs). Identify areas of potential challenge ahead of time and master solutions for all 2024 Proposed IPPS changes.
Do you struggle with selecting and appending the correct modifier for your medical claims? Join our must-attend webinar, “Mastering Modifier Usage: Preventing Denials and Ensuring Compliance” to reduce claim denials and improve your reimbursement rates.
Kay Piper reviews the guidance and updates coders and CDISs on important information in the AHA’s fourth quarter 2023 ICD-10-CM/PCS Quarterly Coding Clinic in an easy to access on-demand webcast.
Copyright © 2023 ICD10monitor. Powered by MedLearn Media.
